(Q43218254)

English

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil

scientific article published on 16 December 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

16 November 2017

Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil (English)

1 reference

Europe PubMed Central

16 November 2017

arterial hypertension

1 reference

based on heuristic

inferred from title

Jérôme Le Pavec

object named as

Jérôme Le Pavec

3

0 references

object named as

Xavier Jais

9

0 references

object named as

Olivier Sitbon

2

0 references

object named as

David Launay

1

0 references

object named as

Marc Humbert

11

0 references

Gérald Simonneau

10

object named as

Gérald Simonneau

1 reference

Europe PubMed Central

16 November 2017

Florence Parent

8

object named as

Florence Parent

1 reference

Europe PubMed Central

16 November 2017

Colas Tcherakian

5

object named as

Colas Tchérakian

1 reference

Europe PubMed Central

16 November 2017

Azzedine Yaïci

6

object named as

Azzedine Yaïci

1 reference

Europe PubMed Central

16 November 2017

7

object named as

Lara Achouh

1 reference

Europe PubMed Central

16 November 2017

author name string

Laurent Savale

4

1 reference

Europe PubMed Central

16 November 2017

publication date

16 December 2009

1 reference

Europe PubMed Central

16 November 2017

1 reference

Europe PubMed Central

16 November 2017

49

1 reference

Europe PubMed Central

16 November 2017

3

1 reference

Europe PubMed Central

16 November 2017

490-500

1 reference

Europe PubMed Central

16 November 2017

Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Risk factors for death and the 3-year survival of patients with systemic sclerosis: the French ItinérAIR-Sclérodermie study

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Changes in causes of death in systemic sclerosis, 1972-2002

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Inhaled iloprost for severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Sildenafil citrate therapy for pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Survival with first-line bosentan in patients with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Systemic sclerosis associated pulmonary hypertension: improved survival in the current era.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Treatment of pulmonary arterial hypertension

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Haemodynamic evaluation of pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Clinical differences between idiopathic and scleroderma-related pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Cardiac magnetic resonance imaging in systemic sclerosis: a cross-sectional observational study of 52 patients

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France

1 reference

https://api.crossref.org/works/10.1093%2FRHEUMATOLOGY%2FKEP398

21 January 2018

Identifiers

10.1093/RHEUMATOLOGY/KEP398

1 reference

Europe PubMed Central

16 November 2017

1 reference

Europe PubMed Central

16 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43218254&oldid=1984110604"